On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...

Pi Health is to deliver outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of ...

Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...

As China's biotech sector continues to buzz with innovation, the country is rapidly integrating into the global clinical ...

Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...

AstraZeneca’s Saphnelo (SC) administration has shown a decrease in disease activity in individuals with systemic lupus ...

Nektar Therapeutics has presented data of its atopic dermatitis (AD) candidate rezpeg (rezpegaldesleukin), which sent the ...

PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing correction in a Phase I trial.

Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.

The main concerns about tariffs that businesses have are higher input costs and uncertainty in long-term planning.

Trially has raised $4.7m in a seed funding round and introduced its agentic AI solution, Margo, designed to increase study ...

Johnson & Johnson said the combination was investigated in 49 patients with newly diagnosed multiple myeloma. Image credit: PixelBiss / Shutterstock.com Johnson & Johnson’s (J&J’s) multiple myeloma ...